Clinical Next-Gen Tumor Sequencing: Your Key to the
Value-Driven Oncology Market


$1,195.00 $297.00



View table of contents

“As the paradigm shifts away from ‘one drug fits all’ to ‘mechanism-matched’ trials, NGS is becoming a necessity. Partnerships with pharmaceutical companies or CROs have the promise to drive revenues for early adopters.” – Excerpt, Clinical Next-Gen Tumor Sequencing

Because of the cost and quality of care challenges, payers have identified oncology as a key target for value improvement.

And yet, various pilot programs have not yet thoroughly examined the role of next-generation sequencing (NGS) in value improvement — even though it has the potential to lower the cost and improve the quality of cancer care.

That’s where Clinical Next-Gen Tumor Sequencing comes in.

This new report from G2 Intelligence is the ONLY comprehensive resource that covers the how, why and best practices of NGS for oncology — PLUS projections, analysis, and value-based benefits for your organization.

Its main purpose is to evaluate clinical adoption of NGS in oncology to date, including both clinical trials and commercial clinical testing for cancer patient care, and project future adoption.

Inside, you’ll find a wealth of exclusive, hard-to-find intelligence including:

  • Overview and Trends
  • Next-Generation Sequencing: Oncology, with discussions on:
    • Cost Curve Decline: Faster than Moore’s Law
    • NGS Tumor Profiling: Tumor Markers and Targeted Therapies
    • NGS Vendors, Regulatory and Validation Landscape, and Reimbursemen
  • Clinical Adoption: An Inflection Point Nears, featuring:
    • Primary Factors that Hindered Clinical NGS Adoption
    • From Barriers to Drivers: NGS Adoption Dynamics Changing
    • Paradigm Shift in Oncology Clinical Trials
  • Early Adopters: Approaches, Opportunities, and Challenges, with:
    • Implementing NGS Oncology Testing
    • Case Studies
    • Market Opportunities for Early Adopters
    • Challenges Facing Early Adopters
  • Competing in a Value-Driven Market, with insights on
    • Role of NGS in a Value-Driven Market
    • NGS Market Entry: Four Key Value Strategies for Clinical Laboratories
    • The NGS Value Advantage
  • APPENDIX A: NGS Platforms from Leading Vendors
  • APPENDIX B: FDA-Approved Cancer Drugs and Associated Biomarkers


Authored by G2’s Industry Experts

Jenny Xu, Ph.D., Director of Research

Xu joins G2 from the global consultancy, ZS Associates. Her experience also includes full service market research firm, Harris Interactive. She earned her Ph.D. with honors from the Annenberg School for Communication at the University of Southern California.

L. Eleanor J. Herriman, M.D., M.B.A., Managing Director, Advisory Services

Herriman’s 15+ years of market experience spans the clinical laboratory, IVD, and strategy consulting for Bain & Company. She earned her M.D. at Baylor College of Medicine, and received an M.B.A. from Harvard Business School.

Order below or call Customer Service at 888-729-2315 (8am – 5pm ET).

For multi-user/multi-location pricing, please contact Andrea at 888-729-2315 or via email at